Endometrial carcinoma: Immunohistochemically detected proliferation index is a prognosticator of long term outcome

Journal of Clinical Pathology

Volumn 51, Issue 1, 1998, Pages 25-29

  Gassel, A M ^a   Backe, J ^a   Krebs, S ^a   Schon S ^a   Caffier, H ^a   Muller Hermelink H K ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Endometrial carcinoma; Prognosticators; Proliferation rate

Indexed keywords

ARTICLE; CANCER GRADING; CANCER SURVIVAL; CELL PROLIFERATION; ENDOMETRIUM CARCINOMA; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MITOSIS INDEX; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TUMOR VOLUME;

EID: 0031912186     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.51.1.25     Document Type: Article

References (38)

1. Creasman WT. Adenocarcinoma of the uterine corpus. Curr Opin Obstet Gynecol 1992;5:80-3.
2. Kadar N, Malfetano JH, Homesley HD. Determinants of survival of surgically staged patients with endometrial carcinoma histologically confined to the uterus: implications for therapy. Obstet Gynecol 1992;80:655-9.
3. Wolfson AH, Sightler SE, Markoe AM, et al. The prognostic significance of surgical staging for carcinoma of the endometrium. Gynecol Oncol 1992;45:142-6.
4. Creasman WT, Morrow CP, Bundy L, et al. Surgical pathological spread patterns of endometrial cancer. Cancer 1987; 60:2035-41.
5. Schink JC, Rademaker AW, Miller DS, et al. Tumour size in endometrial cancer. Cancer 1991;67:2791-4.
6. Creasman WT. Prognostic significance of hormone receptors in endometrial cancers. Cancer 1993;71:1467-70.
7. Khalifa MA, Mannel RS, Haraway SD, et al. Expression of EGFR, HER-2/neu, p53, and PCNA in endometrioid, serous papillary and clear cell endometrial adenocarcinomas. Gynecol Oncol 1994;53:84-92.
8. Pisani AL, Barbuto DA, Chen D, et al. HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma. Obstet Gynecol 1995;85:729-34.
9. Creasman, WT. Announcement, FIGO stages: 1988 revision. Gynecol Oncol 1989;35:125-7.
10. Kreipe H-H, Alm P, Olsson H, et al. Prognostic significance of a formalin resistant nuclear proliferation antigen in mammary carcinomas as determined by the monoclonal antibody Ki-Sl. Am J Pathol 1993;142:651-7.
11. Remmele W, Stegner HE. Vorschlag zur einheitlichen definition eines immunreaktiven score (IRS) für den immunhistochemischen östrogenrezeptor nachweis im mammakarzinomgewebe. Pathologe 1987;8:138-40.
12. Segreti EM, Novotny DB, Soper JT, et al. Endometrial cancer: histologic correlates of immunohistochemical localization of progesterone and estrogen receptor. Obstet Gynecol 1989;73:780-5.
13. Pezzella F, Micklem K, Turley H, et al. Antibody for detecting p53 protein by immunohistochemistry in normal tissues. J Clin Pathol 1994;47:592-6.
14. Göhring U-J, Scharl A, Thelen U, et al. Prognostic value of cathepsin D in breast cancer: comparison of immunohistochemical and immunoradiometric detection methods. J Clin Pathol 1996;49:57-64.
15. Christopherson WM, Connelly PJ, Alberhasky RC. Carcinoma of the endometrium. V. An analysis of prognosticators in patients with favorable subtypes and stage I disease. Cancer 1983;51:1705-10.
16. Kurman RJ, Norris HJ. Endometrial carcinomas. In: Kurman RJ, ed. Blaustein's pathology of the female genital tract. New York: Springer, 1994:338-72.
17. Dallenbach F, Stein H, Dallenbach FD. Proliferationsmarker bei endometriumkarzinomen verschiedener histogenese: Vergleich immunhistologischer untersuchungen an kryostat-und paraffinschnitten. Verh Dtsch Ges Path 1991;75:375.
18. Maentausta O, Boman K, Isomaa V, et al. Immunohistochemical study of the human 17β-hydroxysteroid dehydrogenase and steroid receptors in endometrial adenocarcinoma. Cancer 1992;70:1551-5
19. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell-proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133: 1710-15.
20. Yabushita H, Masuda T, Sawaguchi K, et al. Growth potential of endometrial cancers assessed by a Ki-67 Ag DNA dual-color flow-cytometric assay. Gynecol Oncol 1992;443: 263-7.
21. Nielsen AL, Nyholm CJ. Proliferative activity as revealed by Ki-67 in uterine adenocarcinoma of endometroid type: comparison of tumours from patients with and without previous estrogen therapy. J Pathol 1993;171:199-205.
22. Dallenbach-Hellweg G, Lang-Averous G, Hahn U. The value of immunohistochemistry in the differential diagnosis of endometrial carcinomas. APMIS 1991;23(suppl):91-9.
23. Garzetti GG, Ciavattani A, Goteri G, et al. Proliferating cell nuclear antigen in endometrial carcinoma: pretreatment identification of high-risk patients. Gynecol Oncol 1996;61: 16-21.
24. Geisler JP, Wiemann MC, Zhou Z, et al. Proliferation index determined by MIB-1 and recurrence in endometrial cancer. Gynecol Oncol 1996;61:373-7.
25. Hamel NW, Sebo TJ, Wilson TO, et al. Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma. Gynecol Oncol 1996;62:192-8.
26. Porter PL, Gown AM, Kramp SG, et al. Widespread p53 overexpression in human malignant tumours. Am J Pathol 1992;140:145-53.
27. Poremba C, Bankfalvi A, Dockhorn-Dworniczak B. Das tumoursuppressorgen p53. Pathologe 1996;17:181-8.
28. Berchuck A, Kohler MF, Mark JR, et al. The p53 tumour suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol 1994;170:246-52.
29. Okamoto A, Sameshima Y, Yamada Y, et al. Allelic chromosome 17p and p53 mutations in human endometrial carcinoma of the uterus. Cancer Res 1992;52:6079-82.
30. Ambros RA, Vigna PA, Figge J, et al. Observations on tumour and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53. Cancer 1994;73:1686-92.
31. Inoue M, Okayama A, Fujita M, et al. Clinicopathological characteristics of p53 overexpression in endometrial cancers. Int J Cancer 1994;58:14-19.
32. Kohler MF, Berchuck A, Davidoff AM, et al. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 1992;52:1622-7.
33. Nazeer T, Curch K, Amato C, et al. Comparative quantitative immunohistochemical and immunoradiometric determinations of cathepsin D in endometrial adenocarcinoma: predictors of tumour aggressiveness. Mod Pathol 1994;7: 469-74.
34. Nazeer T, Malfetano JH, Rosano TG, et al. Correlation of tumour cytosol cathepsin D with differentiation and invasiveness of endometrial adenocarcinoma. J Clin Pathol 1992;97:764-9.
35. Saffari B, Jones LA, el Naggar A, et al. Amplification and overexpression of HER-2/neu (c-erbB-2) in endometrial cancers: correlation with overall survival. Cancer Res 1995; 55:5693-8.
36. Wang D, Konishi J, Koshiyama M, et al. Expression of c-erbB-2 protein and epidermal growth factor receptor in endometrial carcinomas. Cancer 1993;72:2628-37.
37. Kohlberger P, Loesch A, Koelbl H, et al. Prognostic value of immunohistochemically detected HER-2 neu oncoprotein in endometrial cancer. Cancer Lett 1996;98:151-5.
38. Bigsby RM, Aixin L, Bomalaski J, et al. Immunohistochemical study of HER-2/neu, epidermal growth factor receptor, and steroid receptor expression in normal and malignant endometrium. Obstet Gynecol 1992;79:95-100.